Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Flockhart

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Breast Cancer Research and Treatment|March 17, 2005
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman, Chris Benz, Arul Chinnaiyan, et al.
BMC Bioinformatics|February 5, 2013
An integrated pharmacokinetics ontology and corpus for text miningHeng-Yi Wu, Shreyas Karnik, Abhinita Subhadarshini, et al.
Menopause (New York, N.Y.)|May 21, 2009
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapyJulie L Otte, David Flockhart, Daniel Hayes, et al.
British Journal of Clinical Pharmacology|February 18, 2014
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associationsYuan Ji, Daniel J Schaid, Zeruesenay Desta, et al.
Springerplus|March 12, 2013
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancerRichard R Love, Zuerenesay Desta, David Flockhart, et al.
Breast Cancer Research and Treatment|October 9, 2007
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitorsN Lynn Henry, Jon T Giles, Dennis Ang, et al.
Pharmacogenomics|May 1, 2007
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharingRuss B Altman, Neal Benowitz, David Gurwitz, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Breast Cancer Research and Treatment|March 17, 2005
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman, Chris Benz, Arul Chinnaiyan, et al.
BMC Bioinformatics|February 5, 2013
An integrated pharmacokinetics ontology and corpus for text miningHeng-Yi Wu, Shreyas Karnik, Abhinita Subhadarshini, et al.
Menopause (New York, N.Y.)|May 21, 2009
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapyJulie L Otte, David Flockhart, Daniel Hayes, et al.
British Journal of Clinical Pharmacology|February 18, 2014
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associationsYuan Ji, Daniel J Schaid, Zeruesenay Desta, et al.
Springerplus|March 12, 2013
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancerRichard R Love, Zuerenesay Desta, David Flockhart, et al.
Breast Cancer Research and Treatment|October 9, 2007
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitorsN Lynn Henry, Jon T Giles, Dennis Ang, et al.
Pharmacogenomics|May 1, 2007
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharingRuss B Altman, Neal Benowitz, David Gurwitz, et al.
Pageof 3